Research Information System
Endocrinology research and practice, vol.27, no.3, pp.158-163, 2023 (Peer-Reviewed Journal)
Objective: One of many theories for the cause of osteoporosis in prolactinoma is the increased level of the parathyroid hormone-related peptide. We aimed to assess the parathyroid hormone-related pep tide levels and its potential effects on bone mineral density in patients with eugonadal prolactinoma. Methods: We enrolled 29 eugonadal prolactinoma patients and 31 controls. Serum prolactin, thyroid function tests, calcium, phosphorus, albumin, gonadal steroids, parathyroid hormone, 25-OH vita min D, alkaline phosphatase, 24-hour urine calcium, parathyroid hormone-related peptide, and bone mineral density were measured. Results: No statistically significant difference was observed in parathyroid hormone-related peptide levels between the prolactinoma and the control groups (P=.288). The parathyroid hormone-related peptide levels were significantly higher in men in both groups (P < .05). No relationship was observed between the parathyroid hormone-related peptide levels and bone mineral density in g/cm2 for lum bar vertebrae, femur, and radius (P > .05). Although there was also no significant correlation between parathyroid hormone-related peptide and Z scores of lumbar vertebrae and femur (P > .05), Z scores of radius were significantly correlated with parathyroid hormone-related peptide (P=.001, r=-0.575). Conclusion: To the best of our knowledge, contrary to hypotheses that the elevated level of para thyroid hormone-related peptide may be one of the factors contributing to osteoporosis in prolac tinoma patients, this is the first study revealing that parathyroid hormone-related peptide has no significant impact on osteoporosis in eugonadal prolactinoma patients. Furthermore, this is the first study to demonstrate gender differences in physiological parathyroid hormone-related peptide lev els. However, additional studies with large samples are required to confirm these finding.